Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWang Li

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows 90.9% complete response rate in high-risk relapsed large B-cell lymphoma, suggesting immunotherapy may enhance outcomes.

Key Points

  • Glofitamab plus CD19 CAR-T therapy achieves 90.9% complete response rate in high-risk relapsed large B-cell lymphoma.
  • 26 patients were evaluated, with an average complete response rate of 65.4% following initial treatment.
  • The approach involved leukapheresis, obinutuzumab treatment, and eventual CAR-T infusion with immunotherapy.
  • Findings highlight the potential for an immunotherapy-driven approach to improve outcomes in high-risk patients.

Cite This Study

Wang Li (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5b5https://doi.org/10.1182/blood-2025-3744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  2. 2Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study2025
  5. 5Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025